<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00409825</url>
  </required_header>
  <id_info>
    <org_study_id>IRB #0603056</org_study_id>
    <secondary_id>5U10HD047905-02</secondary_id>
    <nct_id>NCT00409825</nct_id>
  </id_info>
  <brief_title>Study of Pharmacology of 17-OHPC in Pregnancy</brief_title>
  <official_title>A Study of the Pharmacology of 17-Hydroxyprogesterone Caproate in Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We are examining the pharmacology of 17-OHPC in pregnancy, specifically between the second
      and third trimesters.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The recently completed trial by the National Institute of Child Health and Human Development
      (NICHD)-sponsored Maternal-Fetal Medicine Units (MFMU) Network has demonstrated that
      intramuscular 17-alpha-hydroxyprogesterone caproate (17-OHPC) substantially reduces the rate
      of preterm birth in women at high risk for preterm delivery because of a prior spontaneous
      preterm birth. No other strategy or treatment for prevention of preterm birth has proven to
      be effective. Consequently, the American College of Obstetricians and Gynecologists has
      cautiously supported this treatment but points out that much more information about this
      therapy and alternative therapies is required. Although a large body of evidence exists about
      the safety of this treatment, almost nothing is known about the pharmacology of this agent,
      especially in pregnancy. The purpose of this study is to define the pharmacology of
      17-hydroxyprogesterone caproate in pregnancy. This protocol will focus on pharmacokinetics
      and placental transport and provide preliminary data on the pharmacoepidemiology of 17-OHPC.
      The primary research question of this study is: Do the pharmacokinetics of 17-OHPC as
      represented by area under the concentration vs. time curve after IM injection of 250 mg
      17-OHPC differ between the second and third trimesters of pregnancy? We will obtain blood
      samples prior to and daily for one week after injection of 17-OHPC (8 samples total) for each
      of two parts of the study, with an optional third part for eligible subjects. Additionally,
      blood samples will be collected prior to each weekly injection of the study drug and at time
      of delivery. Approximately 60 subjects (ages 18-45) will be accrued at one of the Obstetrical
      Fetal Pharmacology Research Units (OPRU) Network sites, with 15 at Magee-Womens Hospital of
      the University of Pittsburgh Medical Center. Study treatment will be administered until
      delivery. The total duration of this multi-center study is 2-3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Area Under the Concentration vs. Time Curve in the Second and Third Trimesters of Pregnancy.</measure>
    <time_frame>Second and third trimesters of pregnancy</time_frame>
    <description>Change in the area under the concentration vs. time curve in the second and third trimesters of pregnancy.
We compared AUC at each PK study visit. Measurements were obtained at 0, 1, 2, 3, 4, 5, 6, 7 days.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1 done after 4 weekly 17-OHPC injections completed, between 20 6/7 to 24 6/7 weeks gestation. 10 cc blood drawn pre-5th injection. 10 cc blood drawn 12 hours post-dose and 7 consecutive days. 24-hour urine collected days 4-5 within 7 days post-injection. Part 2 done 31 0/7 to 34 6/7 or at 35 0/7 weeks. 10 cc blood drawn pre weekly injection, 12 hours post-dose, and 7 consecutive days. 24-hour urine collected between days 4-5 within 7 days post-injection. A subject in whom Part 2 is performed during the last scheduled injection of 17-OHPC (at or around 35 0/7 weeks) will have the option to participate in Part 3, in which 10 cc of blood will be drawn serially over 21 days after completing Part 2. Blood will be drawn on days 9, 11, 14, 17, 20, 24, 28 after the last injection. Part 4: At the time of labor and delivery, subject will have 10cc of blood removed from a maternal peripheral vein. 10cc of blood will be collected from the placenta/umbilical cord after delivery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>17-OHPC</intervention_name>
    <description>Intra-muscular injection of 250 mg 17-OHPC administered weekly between the second and third trimesters of pregnancy, until time of delivery.</description>
    <arm_group_label>Part 1</arm_group_label>
    <other_name>17-alpha-hydroxyprogesterone caproate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood Draws</intervention_name>
    <description>10 cc of blood will be drawn prior to the fifth weekly administration of 17-OHPC during second trimester of pregnancy, and then once daily for seven consecutive days post-dose. 10 cc of blood also will be drawn prior to weekly administration of 17-OHPC from sixth weekly dose in the second trimester until the last scheduled dose in the third trimester. Prior to this last scheduled dose, 10 cc of blood will be drawn, as well as once daily for seven consecutive days post-dose.</description>
    <arm_group_label>Part 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Singleton gestation prior to 20 0/7 weeks gestation

          -  Planning to receive or receiving 17-OHPC (250 mg IM weekly)

          -  Previous history of preterm birth

          -  Able to give consent

        Exclusion Criteria:

          -  Fetal demise, anomaly, or growth restriction

          -  Hepatic or renal dysfunction

          -  Placental previa or abruptio placenta

          -  Polyhydramnios/oligohydramnios

          -  Short cervix or planned cerclage

          -  Chronic use of steroids, antiepileptics, antihypertensives, SSRS, street drugs

          -  Participation in another interventional study that influences gestational age at
             delivery

          -  Heparin treatment of known platelet count &lt;100,000/mm3 (because of contraindication to
             intra-muscular injections)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve N. Caritis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magee-Womens Hospital of University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, Spong CY, Hauth JC, Miodovnik M, Varner MW, Leveno KJ, Caritis SN, Iams JD, Wapner RJ, Conway D, O'Sullivan MJ, Carpenter M, Mercer B, Ramin SM, Thorp JM, Peaceman AM, Gabbe S; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003 Jun 12;348(24):2379-85. Erratum in: N Engl J Med. 2003 Sep 25;349(13):1299.</citation>
    <PMID>12802023</PMID>
  </reference>
  <reference>
    <citation>ACOG News Release: Progesterone recommended in certain high risk pregnancies to help prevent preterm birth. October 31, 2003</citation>
  </reference>
  <reference>
    <citation>Onsrud M, Paus E, Haug E, Kjørstad K. Intramuscular administration of hydroxyprogesterone caproate in patients with endometrial carcinoma. Pharmacokinetics and effects on adrenal function. Acta Obstet Gynecol Scand. 1985;64(6):519-23.</citation>
    <PMID>2932883</PMID>
  </reference>
  <reference>
    <citation>Kiesling H, Elmquist A: Acta Endocrinol 28:502, 1958</citation>
  </reference>
  <reference>
    <citation>GASSNER FX, MARTIN RP, SHIMODA W, ALGEO JW. Metaolism of radioactive steroid esters in the bovine male and female. Fertil Steril. 1960 Jan-Feb;11:49-73.</citation>
    <PMID>13826776</PMID>
  </reference>
  <reference>
    <citation>Langecker J, Harwart A, Junkmann K: Arch exptl Pathol. Pharacol 225:309, 1955.</citation>
  </reference>
  <reference>
    <citation>WIENER M, LUPU CI, PLOTZ EJ. Metabolism of 17 alpha-hydroxyprogesterone-4-C14-17 alpha-caproate by homogenates of rat liver and human placenta. Acta Endocrinol (Copenh). 1961 Apr;36:511-9.</citation>
    <PMID>13785108</PMID>
  </reference>
  <reference>
    <citation>Endocrinology &amp; human gestation. IN: Reproductive Endocrinology, p458. Edited by EY Adashi, Lippincott-Raven Publishers, Philadelphia, PA 1996.</citation>
  </reference>
  <reference>
    <citation>Challis JRG, Matthews SG, Gibb W, Lye SJ. Endocrine and paracrine regulation of birth at term and preterm. Endocr Rev. 2000 Oct;21(5):514-50. Review.</citation>
    <PMID>11041447</PMID>
  </reference>
  <reference>
    <citation>Johnson JW, Lee PA, Zachary AS, Calhoun S, Migeon CJ. High-risk prematurity--progestin treatment and steroid studies. Obstet Gynecol. 1979 Oct;54(4):412-8.</citation>
    <PMID>492618</PMID>
  </reference>
  <reference>
    <citation>Keirse MJ. Progestogen administration in pregnancy may prevent preterm delivery. Br J Obstet Gynaecol. 1990 Feb;97(2):149-54.</citation>
    <PMID>2138496</PMID>
  </reference>
  <reference>
    <citation>da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol. 2003 Feb;188(2):419-24.</citation>
    <PMID>12592250</PMID>
  </reference>
  <reference>
    <citation>Csapo AI. The 'see-saw' theory of parturition. Ciba Found Symp. 1977;(47):159-210.</citation>
    <PMID>246391</PMID>
  </reference>
  <reference>
    <citation>Haluska GJ, Wells TR, Hirst JJ, Brenner RM, Sadowsky DW, Novy MJ. Progesterone receptor localization and isoforms in myometrium, decidua, and fetal membranes from rhesus macaques: evidence for functional progesterone withdrawal at parturition. J Soc Gynecol Investig. 2002 May-Jun;9(3):125-36.</citation>
    <PMID>12009386</PMID>
  </reference>
  <reference>
    <citation>Lye S: Personal communication</citation>
  </reference>
  <reference>
    <citation>JUNKMANN K. [Estrogens with prolonged action]. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1953;220(5):358-64. Undetermined Language.</citation>
    <PMID>13144797</PMID>
  </reference>
  <reference>
    <citation>KESSLER WB, BORMAN A. Some biological activities of certain progestogens. I. 17 alpha-Hydroxyprogesterone 17-n-caproate. Ann N Y Acad Sci. 1958 Jul 30;71(5):486-93.</citation>
    <PMID>13583805</PMID>
  </reference>
  <reference>
    <citation>JOHNSTONE EE, FRANKLIN RR. ASSAY OF PROGESTINS FOR FETAL VIRILIZING PROPERTIES USING THE MOUSE. Obstet Gynecol. 1964 Mar;23:359-62.</citation>
    <PMID>14128463</PMID>
  </reference>
  <reference>
    <citation>SUCHOWSKY G, JUNKMANN K. [Research on the maintenance of pregnancy by 17 alpha-hydroxyprogesterone caproate in the castrated pregnant rabbit]. Acta Endocrinol (Copenh). 1958 Jun;28(2):129-31. German.</citation>
    <PMID>13532385</PMID>
  </reference>
  <reference>
    <citation>Courtney KD, Valerio DA. Teratology in the Macaca mulatta. Teratology. 1968 May;1(2):163-72.</citation>
    <PMID>4321743</PMID>
  </reference>
  <reference>
    <citation>Carbone JP, Brent RL. Genital and nongenital teratogenesis of prenatal progestogen therapy: the effects of 17 alpha-hydroxyprogesterone caproate on embryonic and fetal development and endochondral ossification in the C57B1/6J mouse. Am J Obstet Gynecol. 1993 Nov;169(5):1292-8.</citation>
    <PMID>8238197</PMID>
  </reference>
  <reference>
    <citation>Seegmiller RE, Nelson GW, Johnson CK. Evaluation of the teratogenic potential of delalutin (17 alpha-hydroxyprogesterone caproate) in mice. Teratology. 1983 Oct;28(2):201-8.</citation>
    <PMID>6648824</PMID>
  </reference>
  <reference>
    <citation>Varma TR, Morsman J. Evaluation of the use of Proluton-Depot (hydroxyprogesterone hexanoate) in early pregnancy. Int J Gynaecol Obstet. 1982 Feb;20(1):13-7.</citation>
    <PMID>6126401</PMID>
  </reference>
  <reference>
    <citation>Michaelis J, Michaelis H, Glück E, Koller S. Prospective study of suspected associations between certain drugs administered during early pregnancy and congenital malformations. Teratology. 1983 Feb;27(1):57-64.</citation>
    <PMID>6845218</PMID>
  </reference>
  <reference>
    <citation>Resseguie LJ, Hick JF, Bruen JA, Noller KL, O'Fallon WM, Kurland LT. Congenital malformations among offspring exposed in utero to progestins, Olmsted County, Minnesota, 1936-1974. Fertil Steril. 1985 Apr;43(4):514-9.</citation>
    <PMID>3987922</PMID>
  </reference>
  <reference>
    <citation>Check JH, Rankin A, Teichman M. The risk of fetal anomalies as a result of progesterone therapy during pregnancy. Fertil Steril. 1986 Apr;45(4):575-7.</citation>
    <PMID>3956772</PMID>
  </reference>
  <reference>
    <citation>Katz Z, Lancet M, Skornik J, Chemke J, Mogilner BM, Klinberg M. Teratogenicity of progestogens given during the first trimester of pregnancy. Obstet Gynecol. 1985 Jun;65(6):775-80.</citation>
    <PMID>3158848</PMID>
  </reference>
  <reference>
    <citation>Kester PA. Effects of prenatally administered 17 alpha-hydroxyprogesterone caproate on adolescent males. Arch Sex Behav. 1984 Oct;13(5):441-55.</citation>
    <PMID>6517685</PMID>
  </reference>
  <reference>
    <citation>Schardein JL. Congenital abnormalities and hormones during pregnancy: a clinical review. Teratology. 1980 Dec;22(3):251-70. Review.</citation>
    <PMID>7015547</PMID>
  </reference>
  <reference>
    <citation>Raman-Wilms L, Tseng AL, Wighardt S, Einarson TR, Koren G. Fetal genital effects of first-trimester sex hormone exposure: a meta-analysis. Obstet Gynecol. 1995 Jan;85(1):141-9.</citation>
    <PMID>7800312</PMID>
  </reference>
  <reference>
    <citation>Reprotox Database. Hydroxyprogesterone 17-. Reprotox. org. March 1, 2003.</citation>
  </reference>
  <reference>
    <citation>Florey K: Hydroxyprogesterone caproate. IN: Analytical profiles of drug substances. Vol 4. 208-224 Editors: Academic Press, NY, NY, 1975.</citation>
  </reference>
  <reference>
    <citation>REIFENSTEIN EC Jr. Introduction of marked as well as prolonged biologic activity by esterification; 17-alpha-hydroxyprogesterone caproate, a unique progestational compound. Fertil Steril. 1957 Jan-Feb;8(1):50-79.</citation>
    <PMID>13405048</PMID>
  </reference>
  <reference>
    <citation>Karalis K, Goodwin G, Majzoub JA. Cortisol blockade of progesterone: a possible molecular mechanism involved in the initiation of human labor. Nat Med. 1996 May;2(5):556-60.</citation>
    <PMID>8616715</PMID>
  </reference>
  <reference>
    <citation>Hvilsom GB, Thorsen P, Jeune B, Bakketeig LS. C-reactive protein: a serological marker for preterm delivery? Acta Obstet Gynecol Scand. 2002 May;81(5):424-9.</citation>
    <PMID>12027816</PMID>
  </reference>
  <reference>
    <citation>Mackler AM, Iezza G, Akin MR, McMillan P, Yellon SM. Macrophage trafficking in the uterus and cervix precedes parturition in the mouse. Biol Reprod. 1999 Oct;61(4):879-83.</citation>
    <PMID>10491619</PMID>
  </reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2006</study_first_submitted>
  <study_first_submitted_qc>December 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2006</study_first_posted>
  <results_first_submitted>January 13, 2015</results_first_submitted>
  <results_first_submitted_qc>January 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 9, 2015</results_first_posted>
  <last_update_submitted>February 9, 2015</last_update_submitted>
  <last_update_submitted_qc>February 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>17-alpha-hydroxy-progesterone caproate</mesh_term>
    <mesh_term>11-hydroxyprogesterone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AUC1 vs AUC2</title>
          <description>AUC 1 done after 4 weekly 17-OHPC injections completed, between 20 6/7 to 24 6/7 weeks gestation. 10 cc blood drawn pre-5th injection. 10 cc blood drawn 12 hours post-dose and 7 consecutive days. 24-hour urine collected days 4-5 within 7 days post-injection.
AUC 2 done 31 0/7 to 34 6/7 or at 35 0/7 weeks. 10 cc blood drawn pre weekly injection, 12 hours post-dose, and 7 consecutive days. 24-hour urine collected between days 4-5 within 7 days post-injection.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AUC1 vs AUC2</title>
          <description>AUC 1 done after 4 weekly 17-OHPC injections completed, between 20 6/7 to 24 6/7 weeks gestation. 10 cc blood drawn pre-5th injection. 10 cc blood drawn 12 hours post-dose and 7 consecutive days. 24-hour urine collected days 4-5 within 7 days post-injection.
AUC 2 done 31 0/7 to 34 6/7 or at 35 0/7 weeks. 10 cc blood drawn pre weekly injection, 12 hours post-dose, and 7 consecutive days. 24-hour urine collected between days 4-5 within 7 days post-injection.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="61"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.01" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in the Area Under the Concentration vs. Time Curve in the Second and Third Trimesters of Pregnancy.</title>
        <description>Change in the area under the concentration vs. time curve in the second and third trimesters of pregnancy.
We compared AUC at each PK study visit. Measurements were obtained at 0, 1, 2, 3, 4, 5, 6, 7 days.</description>
        <time_frame>Second and third trimesters of pregnancy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part 1</title>
            <description>Part 1 done after 4 weekly 17-OHPC injections completed, between 20 6/7 to 24 6/7 weeks gestation. 10 cc blood drawn pre-5th injection. 10 cc blood drawn 12 hours post-dose and 7 consecutive days. 24-hour urine collected days 4-5 within 7 days post-injection. Part 2 done 31 0/7 to 34 6/7 or at 35 0/7 weeks. 10 cc blood drawn pre weekly injection, 12 hours post-dose, and 7 consecutive days. 24-hour urine collected between days 4-5 within 7 days post-injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Area Under the Concentration vs. Time Curve in the Second and Third Trimesters of Pregnancy.</title>
          <description>Change in the area under the concentration vs. time curve in the second and third trimesters of pregnancy.
We compared AUC at each PK study visit. Measurements were obtained at 0, 1, 2, 3, 4, 5, 6, 7 days.</description>
          <units>ng/ML/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115" spread="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC - 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136" spread="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Part 1</title>
          <description>Part 1 done after 4 weekly 17-OHPC injections completed, between 20 6/7 to 24 6/7 weeks gestation. 10 cc blood drawn pre-5th injection. 10 cc blood drawn 12 hours post-dose and 7 consecutive days. 24-hour urine collected days 4-5 within 7 days post-injection. Part 2 done 31 0/7 to 34 6/7 or at 35 0/7 weeks. 10 cc blood drawn pre weekly injection, 12 hours post-dose, and 7 consecutive days. 24-hour urine collected between days 4-5 within 7 days post-injection. A subject in whom Part 2 is performed during the last scheduled injection of 17-OHPC (at or around 35 0/7 weeks) will have the option to participate in Part 4, in which 10 cc of blood will be drawn serially over 21 days after completing Part 2. Blood will be drawn on days 9, 11, 14, 17, 20, 24, 28 after the last injection. Part 3: At the time of labor and delivery, subject will have 10cc of blood removed from a maternal peripheral vein. 10cc of blood will be collected from the placenta/umbilical cord after delivery.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Steve N. Caritis, MD</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-641-4874</phone>
      <email>scaritis@mail.magee.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

